cetirizine prix acheter clomid sans ordonnance seroquel mg acheter calan online http://www.sust.edu/department/sta/wp-co... http://www.sust.edu/department/sta/wp-co... flagyl 125mg achat baclofene medicament pas cher spironolactone phenergan vente
  • alesse birth control affects synthroid ingredient http://php.trinity.edu/qep/info_lit/site... avodart and ed discount viagra lowest prices price of advair-diskus 40 mg osteoporosis statistics uk generic cialis online http://php.trinity.edu/qep/info_lit/site... http://php.trinity.edu/qep/info_lit/site... difference between dutasteride and finasteride
  • acquista kamagra levitra generico in contrassegno kamagra te koop viagra schweiz rezeptfrei meilleur viagra sans ordonnance avis viagrag pas cher viagra preise schweiz viagra 50 mg viagra commande cialis ordina online a san marino
  • synthroid and the fda does per day for celebrex comparison of spironolactone with drugs http://plants.ifas.ufl.edu/manage/sites/... http://plants.ifas.ufl.edu/manage/sites/... alesse for acne kamagra usa allergic to penicillin amoxil viagra history purchase kamagra on line
    propranolol compra online parlodel pharmacie risperdal comprar online
    cialis medicinale viagra bestellen erfahrung viagra tablette
    comprar cialis seguro 
    pharmacie en ligne france 
    propecia pas cher paris 

    Distant Metastases in Head-and-Neck Squamous Cell Carcinoma Treated with Intensity-modulated Radiotherapy

    Tue, Dec 27, 2011

    Oral Cancer News

    Source: International Journal of Radiation Oncology, Biology and Physics (IJROBP Online)

    December 2011

    PURPOSE: To determine the pattern and risk factors for distant metastases in head-and-neck squamous cell carcinoma (HNSCC) after curative treatment with intensity-modulated radiotherapy (IMRT).

    METHODS AND MATERIALS: This was a retrospective study of 284 HNSCC patients treated in a single institution with IMRT. Sites included were oropharynx (125), oral cavity (70), larynx (55), hypopharynx (17), and unknown primary (17). American Joint Committee on Cancer stage distribution includes I (3), II (19), III (42), and IV (203).

    There were 224 males and 60 females with a median age of 57. One hundred eighty-six patients were treated with definitive IMRT and 98 postoperative IMRT. One hundred forty-nine patients also received concurrent cisplatin-based chemotherapy.

    RESULTS: The median follow-up for all patients was 22.8 months (range, 0.07-77.3 months) and 29.5 months (4.23-77.3 months) for living patients. The 3-year local recurrence-free survival, regional recurrence-free survival, locoregional recurrence-free survival, distant metastasis-free survival, and overall survival were 94.6%, 96.4%, 92.5%, 84.1%, and 68.95%, respectively. There were 45 patients with distant metastasis. In multivariate analysis, distant metastasis was strongly associated with N stage (p = 0.046), T stage (p<0.0001), and pretreatment maximum standardized uptake value of the lymph node (p = 0.006), but not associated with age, gender, disease sites, pretreatment standardized uptake value of the primary tumor, or locoregional control. The freedom from distant metastasis at 3 years was 98.1% for no factors, 88.6% for one factor, 68.3% for two factors, and 41.7% for three factors (p <0.0001 by log-rank test).

    CONCLUSION: With advanced radiation techniques and concurrent chemotherapy, the failure pattern has changed with more patients failing distantly. The majority of patients with distant metastases had no local or regional failures, indicating that these patients might have microscopic distant disease before treatment. The clinical factors identified here should be incorporated in future clinical trials.

    This news story was resourced by the Oral Cancer Foundation, and vetted for appropriateness and accuracy.

    Print Friendly
    Be Sociable, Share!
    , , , ,

    Leave a Reply

    You must be logged in to post a comment.